Share Email Print

Proceedings Paper

Photofrin-PDT for gastric cancer in the era of endoscopic submucosal dissection
Author(s): Yoshiro Nishiwaki; Yoshito Ikematsu; Yuuji Tokunaga; Toshikazu Kanai
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Background: Endoscopic mucosal resection (EMR) was originated to treat early gastric cancer (EGC). EMR was suitable for small, mucosal and well-differentiated adenocarcinoma without ulceration. It was difficult to resect larger tumors en bloc by this method. In recent years, a more useful method, endoscopic submuscosal dissection (ESD) has been developed, which enables en bloc resection of large mucosal lesions. On the contrary, photodynamic therapy (PDT) is applicable to submucosal, poorly differentiated, or carcinoma with ulceration. In the era of ESD, we evaluated the value of Photofrin-PDT. Patients & Methods: We applied PDT to 36 patients including three advanced cancers, who had been excluded from EMR (ESD) and were at high risks for surgery or refused surgery. Four EGC patients who had not been cured by EMR (ESD) were included. Our PDT procedure consisted of polyhematoporphyrin ether/ester administration (Photofrin, 2 mg/Kg) and pulsed excimer dye laser irradiation at 630 nm 48 hours (and 96 hours) after sensitization. Results: Complete response (CR) at three months was obtained in 84% (21/25) of mucosal cancer and in 50% (4/8) of submucosal cancer. Although three patients with an advanced cancer improved but were not cured, quality of their life was maintained. There were no serious side effects except skin photosensitivity. Conclusion: Photofrin-PDT should be applied not only EGC patients who are excluded from ESD and have not been cured by ESD with poor risk for surgery, and have high possibilitiy to be cured by PDT, but also advanced cancer patients for local improvement of lesions.

Paper Details

Date Published: 13 July 2009
PDF: 8 pages
Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73803P (13 July 2009); doi: 10.1117/12.823066
Show Author Affiliations
Yoshiro Nishiwaki, Hamamatsu Medical Ctr. (Japan)
Yoshito Ikematsu, Hamamatsu Medical Ctr. (Japan)
Yuuji Tokunaga, Hamamatsu Medical Ctr. (Japan)
Toshikazu Kanai, Hamamatsu Medical Ctr. (Japan)

Published in SPIE Proceedings Vol. 7380:
Photodynamic Therapy: Back to the Future
David H. Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?